AlphAIAlphAI — Financial news for AI agents
tradingview.com$NVAX

Novavax Reports $68 Million Q3 Revenue, Raises 2026 Revenue Outlook

Novavax reported Q3 2026 revenue of $68.3M, down 3% YoY, with a net loss of $31.4M. The company raised its 2026 revenue outlook to $385M–$415M and adjusted expense guidance. Cash reserves were $627M at quarter-end. Sanofi initiated Phase 3 trials for a combination vaccine and began commercial activities for COVID-19 vaccines. Novavax's XFG-adapted Nuvaxovid received approvals in major markets.

Original reporting
tradingview.com
Published Nov 5, 2026, 1:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Novavax Reports $68 Million Q3 Revenue, Raises 2026 Revenue Outlook — source image
Source · tradingview.com
Decision brief

The 30-second read

$NVAXBullishMed
01

Why it matters

The raised revenue outlook could attract new capital and improve sentiment, though ongoing losses temper enthusiasm.

02

Market read

Earnings and guidance update for a listed biotech, providing fresh data for traders.

03

What to watch

Cash position remains strong, but operating losses persist and market competition is intense.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Novavax filed an 8‑K with the SEC reporting its Q3 results and updated guidance.

Company-level read

Ticker impact

$NVAXBullishHigh confidence
Context

Novavax reported Q3 2026 revenue of $68.3M and raised full-year revenue guidance to $385M‑$415M.

Expected impact

potential upside as market prices in higher revenue expectations

Evidence & confidence

The company lifted its full-year revenue range by over 60% versus prior guidance, a material positive catalyst.

Market effects

Sector

Positive for the vaccine and biotech sector as a peer shows stronger revenue outlook.

Regional

Limited to U.S. biotech investors; no broad regional effect.

Global

Modest, reflects ongoing demand for COVID‑19 and flu combination vaccines.

Counterpoint

What could challenge this read

Guidance may be optimistic given recent revenue decline; investors could be cautious.

Key entities

  • company
    Novavax Inc.

    Biotech firm developing vaccines, ticker NVAX.

Read at source← All news

StoryNovavax Raises 2026 Revenue Guidance After Sanofi Vaccine Milestone

Also covered by

5 outlets

Related articles

$NVAXMed

Novavax Q3 Earnings Call Highlights

Novavax reported Q3 revenue of $68M, down from $70M YoY, with a net loss of $31M, improved from a $202M loss last year. The company reduced expenses by 41% YoY and expects its cash runway to extend into 2029. Novavax plans to start clinical testing for its C. diff vaccine candidate in 2027 and is exploring oncology applications for its Matrix-M adjuvant. The company aims to reduce expenses to $150M-$200M by 2028.

finance.yahoo.com
$NVAXMed

Novavax (NVAX) Q3 2026 Earnings Call Transcript

Novavax (NVAX) reported Q3 2026 earnings, highlighting a $125 million milestone from Sanofi's phase III trial of a combination flu-COVID vaccine. The company expects additional milestones and revenue from partnerships. Novavax also plans to advance its C. diff vaccine candidate and expand into oncology. The company raised its full-year revenue outlook and improved expense guidance.

finance.yahoo.com
$NVAXHighAI 8/10

Novavax Beats On A Narrower Loss And Lifts Its Outlook On Sanofi's $125 Million Milestone, But Its Profitability Target Slides To 2029

Novavax reported a narrower-than-expected Q3 loss of $0.19 per share, beating estimates by $0.18, with revenue of $68.3M, exceeding expectations by $17.7M. The company raised its full-year revenue outlook to $400M, including a $125M milestone from Sanofi. However, profitability is now expected in 2029, pushed back from 2028, due to delayed milestones and reduced recurring revenue.

finviz.com